[Image courtesy of Nvidia]
During Nvidia’s (Nasdaq:NVDA) GTC event, the company introduced BioNeMo Cloud, a new component to their AI Foundations suite. This service, designed to streamline life sciences research, drug discovery and protein engineering, provides researchers with access to pretrained AI models, allowing for customization with proprietary data. Offered as a cloud service, BioNeMo Cloud enables accelerated drug discovery workflows, with multinational biotech company Amgen (Nasdaq:AMGN) and several startups already utilizing the platform.BioNeMo Cloud features pretrained AI models for molecular biology, chemistry and molecular dynamics. The platform allows researchers to fine-tune models with proprietary data, executing AI model inference via web browsers or new cloud APIs. This accelerates drug discovery, molecular identification and protein 3D structure prediction.
Featured models in…